AIDXNasdaqServices-Testing LaboratoriesFiscal year ends December 31
20/20 Biolabs, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.26−0.00 (-0.12%)
Close on Oct 19, 2026
- Market cap
- $2.81M
- P/E (TTM)
- –
- Dividend yield
- –
20/20 Biolabs, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | % of revenue | YoY |
|---|---|---|---|---|
| OneTest [Member] | $1.80M | $1.49M | 88.2% | +21.0% |
| BioCheck [Member] | $152.05K | $177.28K | 7.4% | -14.2% |
| CLIAx [Member] | $89.38K | $84.18K | 4.4% | +6.2% |
By region
From the segment and revenue-disaggregation notes of 20/20 Biolabs's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.